LIVIVO - Search results -

Search results

Result 1 - 10 of total 68

Article ; Online: m

Karandashov, Ivan / Kachanov, Artyom / Dukich, Maria / Ponomareva, Natalia / Brezgin, Sergey / Lukashev, Alexander / Pokrovsky, Vadim S / Chulanov, Vladimir / Kostyusheva, Anastasiya / Kostyushev, Dmitry

Viruses

2024 Volume 16, Issue 4

Abstract: The epitranscriptomic modification ... ...

Abstract	The epitranscriptomic modification m
MeSH term(s)	Immunity, Innate ; Humans ; Virus Diseases/immunology ; Virus Diseases/virology ; Methylation ; Virus Replication ; Viruses/immunology ; Viruses/genetics ; Animals ; RNA, Viral/genetics ; RNA, Viral/immunology ; Signal Transduction ; Host-Pathogen Interactions/immunology
Chemical Substances	RNA, Viral
Language	English
Publishing date	2024-04-13
Publishing country	Switzerland
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v16040601
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers.

Kostyushev, Dmitry / Kostyusheva, Anastasiya / Ponomareva, Natalia / Brezgin, Sergey / Chulanov, Vladimir

Nucleic acid therapeutics

2021 Volume 32, Issue 1, Page(s) 14–28

Abstract: After almost a decade of using CRISPR/Cas9 systems to edit target genes, CRISPR/Cas9 and related technologies are rapidly moving to clinical trials. Hepatitis B virus (HBV), which causes severe liver disease, cannot be cleared by modern antivirals, but ... ...

Abstract	After almost a decade of using CRISPR/Cas9 systems to edit target genes, CRISPR/Cas9 and related technologies are rapidly moving to clinical trials. Hepatitis B virus (HBV), which causes severe liver disease, cannot be cleared by modern antivirals, but represents an ideal target for CRISPR/Cas9 systems. Early studies demonstrated very high antiviral potency of CRISPR/Cas9 and supported its use for developing a cure against chronic HBV infection. This review discusses the key issues that must be solved to make CRISPR/Cas9 an anti-HBV therapy.
MeSH term(s)	CRISPR-Associated Protein 9/genetics ; CRISPR-Cas Systems/genetics ; DNA, Circular ; DNA, Viral/genetics ; Hepatitis B/drug therapy ; Hepatitis B/genetics ; Humans
Chemical Substances	DNA, Circular ; DNA, Viral ; CRISPR-Associated Protein 9 (EC 3.1.-)
Language	English
Publishing date	2021-11-19
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2639888-6
ISSN	2159-3345 ; 2159-3337
ISSN (online)	2159-3345
ISSN	2159-3337
DOI	10.1089/nat.2021.0075
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pharmacoeconomic evaluation of the tixagevimab and cilgavimab combination using for pre-exposure prophylaxis of COVID-19

Marina V. Zhuravleva / Vladimir P. Chulanov / Julia V. Gagarina / Elena A. Shabalina

Терапевтический архив, Vol 95, Iss 1, Pp 66-

2023 Volume 77

Abstract: Aim. To evaluate pharmacoeconomic feasibility using of the tixagevimab and cilgavimab combination for pre-exposure prophylaxis of COVID-19 in immunocompromised patients. Materials and methods. Cost-effectiveness of tixagevimab and cilgavimab in persons ... ...

Abstract	Aim. To evaluate pharmacoeconomic feasibility using of the tixagevimab and cilgavimab combination for pre-exposure prophylaxis of COVID-19 in immunocompromised patients. Materials and methods. Cost-effectiveness of tixagevimab and cilgavimab in persons 12 years old who weigh 40 kg and have either a history of allergy that prevents their vaccination against COVID-19 or moderate or immunocompromised was assessed based on PROVENT phase III study results. The quantity of life years or quality-adjusted life years gained was calculated. Direct medical cost associated with prophylaxis of COVID-19, treatment of infected patients and those experiencing long COVID post infection were assessed. Results were compared with wiliness-to-pay threshold, measured as tripled gross domestic product per capita and equal to 2.69 mln RUB in 2022. Results. Pre-exposure prophylaxis of COVID-19 results in additional 0.0287 life years or 0.0247 quality-adjusted life years. The cost of additional life year gained is equal to 1.12 mln RUB, the cost of additional quality-adjusted life years is 1.30 mln RUB. Both costs of additional life year and cost of quality-adjusted life years appeared to be significantly less compared to wiliness-to-pay threshold. Conclusion. Pre-exposure prophylaxis of COVID-19 with combination of tixagevimab and cilgavimab is economically feasible and may be recommended for wide use in Russian healthcare system.
Keywords	covid-19 ; sars-cov-2 ; tixagevimab and cilgavimab ; pharmacoeconomic analysis ; pre-exposure prophylaxis ; cost-effectiveness ; wiliness-to-pay threshold ; Medicine ; R
Language	Russian
Publishing date	2023-02-01T00:00:00Z
Publisher	"Consilium Medicum" Publishing house
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Host-cell interactions in HBV infection and pathogenesis: the emerging role of m6A modification.

Kostyusheva, Anastasiya / Brezgin, Sergey / Glebe, Dieter / Kostyushev, Dmitry / Chulanov, Vladimir

Emerging microbes & infections

2021 Volume 10, Issue 1, Page(s) 2264–2275

Abstract: Hepatitis B virus (HBV) is a DNA virus with a complex life cycle that includes a reverse transcription step. HBV is poorly sensed by the immune system and frequently establishes persistent infection that can cause chronic infection, the leading cause of ... ...

Abstract	Hepatitis B virus (HBV) is a DNA virus with a complex life cycle that includes a reverse transcription step. HBV is poorly sensed by the immune system and frequently establishes persistent infection that can cause chronic infection, the leading cause of liver cancer and cirrhosis worldwide. Recent mounting evidence has indicated the growing importance of RNA methylation (m6A modification) in viral replication, immune escape, and carcinogenesis. The value of m6A RNA modification for the prediction and clinical management of chronic HBV infection remains to be assessed. However, a number of studies indicate the important role of m6A-marked transcripts and factors of m6A machinery in managing HBV-related pathologies. In this review, we discuss the fundamental and potential clinical impact of m6A modifications on HBV infection and pathogenesis, as well as highlight the important molecular techniques and tools that can be used for studying RNA m6A methylome.
MeSH term(s)	Animals ; Hepatitis B/physiopathology ; Hepatitis B/virology ; Hepatitis B virus/genetics ; Hepatitis B virus/metabolism ; Hepatitis B virus/pathogenicity ; Host-Pathogen Interactions ; Humans ; Liver Neoplasms/physiopathology ; Liver Neoplasms/virology ; Methylation
Language	English
Publishing date	2021-11-12
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2681359-2
ISSN	2222-1751 ; 2222-1751
ISSN (online)	2222-1751
ISSN	2222-1751
DOI	10.1080/22221751.2021.2006580
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The menace of severe adverse events and deaths associated with viral gene therapy and its potential solution.

Kachanov, Artyom / Kostyusheva, Anastasiya / Brezgin, Sergey / Karandashov, Ivan / Ponomareva, Natalia / Tikhonov, Andrey / Lukashev, Alexander / Pokrovsky, Vadim / Zamyatnin, Andrey A / Parodi, Alessandro / Chulanov, Vladimir / Kostyushev, Dmitry

Medicinal research reviews

2024

Abstract: Over the past decade, in vivo gene replacement therapy has significantly advanced, resulting in market approval of numerous therapeutics predominantly relying on adeno-associated viral vectors (AAV). While viral vectors have undeniably addressed several ... ...

Abstract	Over the past decade, in vivo gene replacement therapy has significantly advanced, resulting in market approval of numerous therapeutics predominantly relying on adeno-associated viral vectors (AAV). While viral vectors have undeniably addressed several critical healthcare challenges, their clinical application has unveiled a range of limitations and safety concerns. This review highlights the emerging challenges in the field of gene therapy. At first, we discuss both the role of biological barriers in viral gene therapy with a focus on AAVs, and review current landscape of in vivo human gene therapy. We delineate advantages and disadvantages of AAVs as gene delivery vehicles, mostly from the safety perspective (hepatotoxicity, cardiotoxicity, neurotoxicity, inflammatory responses etc.), and outline the mechanisms of adverse events in response to AAV. Contribution of every aspect of AAV vectors (genomic structure, capsid proteins) and host responses to injected AAV is considered and substantiated by basic, translational and clinical studies. The updated evaluation of recent AAV clinical trials and current medical experience clearly shows the risks of AAVs that sometimes overshadow the hopes for curing a hereditary disease. At last, a set of established and new molecular and nanotechnology tools and approaches are provided as potential solutions for mitigating or eliminating side effects. The increasing number of severe adverse reactions and, sadly deaths, demands decisive actions to resolve the issue of immune responses and extremely high doses of viral vectors used for gene therapy. In response to these challenges, various strategies are under development, including approaches aimed at augmenting characteristics of viral vectors and others focused on creating secure and efficacious non-viral vectors. This comprehensive review offers an overarching perspective on the present state of gene therapy utilizing both viral and non-viral vectors.
Language	English
Publishing date	2024-03-28
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	603210-2
ISSN	1098-1128 ; 0198-6325
ISSN (online)	1098-1128
ISSN	0198-6325
DOI	10.1002/med.22036
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1764: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: CRISPR Screening: Molecular Tools for Studying Virus–Host Interactions

Chulanov, Vladimir / Kostyusheva, Anastasiya / Brezgin, Sergey / Ponomareva, Natalia / Gegechkori, Vladimir / Volchkova, Elena / Pimenov, Nikolay / Kostyushev, Dmitry

Viruses. 2021 Nov. 11, v. 13, no. 11

2021

Abstract: CRISPR/Cas is a powerful tool for studying the role of genes in viral infections. The invention of CRISPR screening technologies has made it possible to untangle complex interactions between the host and viral agents. Moreover, whole-genome and pathway- ... ...

Abstract	CRISPR/Cas is a powerful tool for studying the role of genes in viral infections. The invention of CRISPR screening technologies has made it possible to untangle complex interactions between the host and viral agents. Moreover, whole-genome and pathway-specific CRISPR screens have facilitated identification of novel drug candidates for treating viral infections. In this review, we highlight recent developments in the fields of CRISPR/Cas with a focus on the use of CRISPR screens for studying viral infections and identifying new candidate genes to aid development of antivirals.
Keywords	antiviral agents ; development aid ; genes ; host-pathogen relationships ; screening ; technology ; viruses
Language	English
Dates of publication	2021-1111
Publishing place	Multidisciplinary Digital Publishing Institute
Document type	Article
ZDB-ID	2516098-9
ISSN	1999-4915
ISSN	1999-4915
DOI	10.3390/v13112258
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Dead Cas Systems: Types, Principles, and Applications.

Brezgin, Sergey / Kostyusheva, Anastasiya / Kostyushev, Dmitry / Chulanov, Vladimir

International journal of molecular sciences

2019 Volume 20, Issue 23

Abstract: The gene editing tool CRISPR-Cas has become the foundation for developing numerous molecular systems used in research and, increasingly, in medical practice. In particular, Cas proteins devoid of nucleolytic activity (dead Cas proteins; dCas) can be used ...

Abstract	The gene editing tool CRISPR-Cas has become the foundation for developing numerous molecular systems used in research and, increasingly, in medical practice. In particular, Cas proteins devoid of nucleolytic activity (dead Cas proteins; dCas) can be used to deliver functional cargo to programmed sites in the genome. In this review, we describe current CRISPR systems used for developing different dCas-based molecular approaches and summarize their most significant applications. We conclude with comments on the state-of-art in the CRISPR field and future directions.
MeSH term(s)	CRISPR-Associated Protein 9/genetics ; CRISPR-Associated Protein 9/metabolism ; CRISPR-Cas Systems ; Chromatin/chemistry ; Chromatin/metabolism ; Clustered Regularly Interspaced Short Palindromic Repeats ; Communicable Diseases/genetics ; Communicable Diseases/metabolism ; Communicable Diseases/pathology ; Communicable Diseases/therapy ; DNA Methylation ; Epigenesis, Genetic ; Gene Editing/methods ; Genetic Diseases, Inborn/genetics ; Genetic Diseases, Inborn/metabolism ; Genetic Diseases, Inborn/pathology ; Genetic Diseases, Inborn/therapy ; Genome, Human ; Histones/genetics ; Histones/metabolism ; Humans ; Inflammation/genetics ; Inflammation/metabolism ; Inflammation/pathology ; Inflammation/therapy ; Neoplasms/genetics ; Neoplasms/metabolism ; Neoplasms/pathology ; Neoplasms/therapy ; RNA, Guide, CRISPR-Cas Systems/genetics ; RNA, Guide, CRISPR-Cas Systems/metabolism
Chemical Substances	Chromatin ; Histones ; RNA, Guide, CRISPR-Cas Systems ; CRISPR-Associated Protein 9 (EC 3.1.-)
Language	English
Publishing date	2019-11-30
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms20236041
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: CRISPR-Cas systems for diagnosing infectious diseases.

Kostyusheva, Anastasiya / Brezgin, Sergey / Babin, Yurii / Vasilyeva, Irina / Glebe, Dieter / Kostyushev, Dmitry / Chulanov, Vladimir

Methods (San Diego, Calif.)

2021 Volume 203, Page(s) 431–446

Abstract: Infectious diseases are a global health problem affecting billions of people. Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. Currently available diagnostics are very specific and ... ...

Abstract	Infectious diseases are a global health problem affecting billions of people. Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. Currently available diagnostics are very specific and sensitive but time-consuming and require expensive laboratory settings and well-trained personnel; thus, they are not available in resource-limited areas, for the purposes of large-scale screenings and in case of outbreaks and epidemics. Developing new, rapid, and affordable point-of-care diagnostic assays is urgently needed. This review focuses on CRISPR-based technologies and their perspectives to become platforms for point-of-care nucleic acid detection methods and as deployable diagnostic platforms that could help to identify and curb outbreaks and emerging epidemics. We describe the mechanisms and function of different classes and types of CRISPR-Cas systems, including pros and cons for developing molecular diagnostic tests and applications of each type to detect a wide range of infectious agents. Many Cas proteins (Cas3, Cas9, Cas12, Cas13, Cas14 etc.) have been leveraged to create highly accurate and sensitive diagnostic tools combined with technologies of signal amplification and fluorescent, potentiometric, colorimetric, lateral flow assay detection and other. In particular, the most advanced platforms -- SHERLOCK/v2, DETECTR, CARMEN or CRISPR-Chip -- enable detection of attomolar amounts of pathogenic nucleic acids with specificity comparable to that of PCR but with minimal technical settings. Further developing CRISPR-based diagnostic tools promises to dramatically transform molecular diagnostics, making them easily affordable and accessible virtually anywhere in the world. The burden of socially significant diseases, frequent outbreaks, recent epidemics (MERS, SARS and the ongoing COVID-19) and outbreaks of zoonotic viruses (African Swine Fever Virus etc.) urgently need the developing and distribution of express-diagnostic tools. Recently devised CRISPR-technologies represent the unprecedented opportunity to reshape epidemiological surveillance and molecular diagnostics.
MeSH term(s)	African Swine Fever Virus ; Animals ; COVID-19/diagnosis ; COVID-19/epidemiology ; CRISPR-Cas Systems/genetics ; Communicable Diseases/diagnosis ; Communicable Diseases/genetics ; Humans ; Nucleic Acid Amplification Techniques/methods ; Point-of-Care Systems ; Swine
Language	English
Publishing date	2021-04-09
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	1066584-5
ISSN	1095-9130 ; 1046-2023
ISSN (online)	1095-9130
ISSN	1046-2023
DOI	10.1016/j.ymeth.2021.04.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3239: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CRISPR Screening: Molecular Tools for Studying Virus-Host Interactions.

Chulanov, Vladimir / Kostyusheva, Anastasiya / Brezgin, Sergey / Ponomareva, Natalia / Gegechkori, Vladimir / Volchkova, Elena / Pimenov, Nikolay / Kostyushev, Dmitry

Viruses

2021 Volume 13, Issue 11

Abstract	CRISPR/Cas is a powerful tool for studying the role of genes in viral infections. The invention of CRISPR screening technologies has made it possible to untangle complex interactions between the host and viral agents. Moreover, whole-genome and pathway-specific CRISPR screens have facilitated identification of novel drug candidates for treating viral infections. In this review, we highlight recent developments in the fields of CRISPR/Cas with a focus on the use of CRISPR screens for studying viral infections and identifying new candidate genes to aid development of antivirals.
MeSH term(s)	CRISPR-Cas Systems ; Drug Discovery ; Genetic Techniques ; Genome-Wide Association Study/methods ; High-Throughput Screening Assays/methods ; Host Microbial Interactions ; Humans ; Virus Diseases/genetics ; Virus Diseases/virology ; Viruses/genetics
Language	English
Publishing date	2021-11-11
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v13112258
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice.

Malik, Farihah / Chulanov, Vladimir / Pimenov, Nikolay / Fomicheva, Anastasia / Lundin, Rebecca / Levina, Nataliia / Thorne, Claire / Turkova, Anna / Indolfi, Giuseppe

Journal of virus eradication

2022 Volume 8, Issue 1, Page(s) 100063

Abstract: Background: The Russian Federation has the largest paediatric hepatitis C virus (HCV) disease burden in the World Health Organization European region with an estimated 118,000 children living with HCV viraemia. Direct-acting antivirals (DAAs) have been ... ...

Abstract	Background: The Russian Federation has the largest paediatric hepatitis C virus (HCV) disease burden in the World Health Organization European region with an estimated 118,000 children living with HCV viraemia. Direct-acting antivirals (DAAs) have been available for adults in Russia since 2015 and approved for treatment of adolescents aged ≥12 years since 2019. We evaluated DAA availability and uptake for HCV treatment of children and adolescents and clinical practices on diagnosis and management of paediatric HCV in Russia. Methods: A survey was distributed to regional ministries of health in 85 administrative regions during September 2020. The survey consisted of 22 items collecting data on: type of facility, aggregate patient characteristics, HCV testing practices for children and pregnant women and HCV management and treatment practices for children. Results: Survey responses were received from 37 of the 85 regions in Russia (response rate 44%). 2159 children and adolescents with chronic HCV were in follow-up; 1089 (50%) were female. Of 2080 children with available data on age-groups, 134 (6%) were <3 years, 336 (16%) 3-<6 years, 718 (35%) 6-<12 years and 892 (43%) 12-<18 years. 134 (15%) of 892 adolescents ≥12 years received DAAs, 96 (72%) glecaprevir/pibrentasvir, 26 (19%) sofosbuvir, 8 (6%) daclatasvir and 4 (3%) sofosbuvir/ledipasvir. Conclusions: This study provides a baseline of DAA uptake in early stages of rollout for children and adolescents. The use of DAAs for treatment of adolescents in Russia presents a unique opportunity for HCV micro-elimination in this population.
Language	English
Publishing date	2022-02-03
Publishing country	England
Document type	Journal Article
ZDB-ID	2868549-0
ISSN	2055-6659 ; 2055-6640
ISSN (online)	2055-6659
ISSN	2055-6640
DOI	10.1016/j.jve.2022.100063
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito